IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a recombinant, single-chain analog of human Insulin-like Growth Factor-1, modified by an arginine substitution at position 3 and the addition of a 13-amino-acid N-terminal extension. These structural changes are reported in the research literature to reduce the molecule's affinity for IGF-binding proteins, which has in turn been associated with an extended circulating half-life relative to native IGF-1 in experimental contexts. Within the Growth Hormone and Performance category, it is one of several signaling peptides studied in models of cellular growth, tissue metabolism, and the somatotropic axis.

This material is supplied strictly as a research peptide for laboratory and professional reference use. It is not approved by the FDA for therapeutic use, and nothing here should be read as a therapeutic, diagnostic, or treatment claim. Individual results vary in any experimental context, and all characterizations below reflect published preclinical and investigational literature rather than established clinical applications.

• Investigated in preclinical literature in relation to cellular proliferation and protein synthesis signaling; individual results vary
• Studied in research models examining skeletal muscle hypertrophy and tissue growth pathways; individual results vary
• Examined in laboratory settings for IGF-1 receptor binding kinetics and downstream signaling activity
• Referenced in research on glucose uptake and metabolic signaling at the cellular level
• Used as a comparative research tool alongside native IGF-1 in studies of binding-protein interactions and circulating half-life

Reference handling information only. This lyophilized peptide is typically reconstituted with bacteriostatic water (or sterile or acetic-acid solutions per laboratory preference) added slowly against the vial wall and swirled gently rather than shaken to help preserve peptide integrity. Unreconstituted vials are generally stored frozen and protected from light and moisture; once reconstituted, the solution is commonly kept refrigerated (approximately 2-8 degrees C), shielded from light, and used within a limited window consistent with general peptide-stability practices. Repeated freeze-thaw cycles are generally avoided, and material is handled under appropriate aseptic conditions. All reconstitution media, concentrations, storage durations, and any clinical protocols are determined solely by the licensed ordering provider at their professional discretion; this is reference information for research and professional use only and is not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the published research literature, IGF-1 LR3 is described as an agonist of the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase whose activation is associated with downstream PI3K/Akt and MAPK signaling cascades implicated in cell growth, proliferation, and protein synthesis. The position-3 arginine substitution and N-terminal extension are reported to lower its binding to IGF-binding proteins (IGFBPs), which in preclinical models has been proposed to increase the fraction of free, receptor-available peptide and prolong its biological activity compared with unmodified IGF-1. These are proposed and studied mechanisms drawn from experimental contexts; individual results vary and no therapeutic effect is implied.